Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Regression of Hodgkin lymphoma after discontinuation of a tumor necrosis factor inhibitor for Crohn's disease: a case report and review of the literature.

Cassaday RD, Malik JT, Chang JE.

Clin Lymphoma Myeloma Leuk. 2011 Jun;11(3):289-92. doi: 10.1016/j.clml.2011.03.018. Epub 2011 Apr 20. Review.

PMID:
21658658
2.

Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.

Behm BW, Bickston SJ.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006893. doi: 10.1002/14651858.CD006893. Review.

PMID:
18254120
3.

Anti tumour necrosis factor as risk factor for free perforations in Crohn's disease? A case-control study.

Eshuis EJ, Griffioen GH, Stokkers PC, Ubbink DT, Bemelman WA.

Colorectal Dis. 2012 May;14(5):578-84. doi: 10.1111/j.1463-1318.2011.02764.x.

PMID:
21848898
4.

Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect.

Iborra M, Beltrán B, Bastida G, Aguas M, Nos P.

J Crohns Colitis. 2011 Apr;5(2):157-61. doi: 10.1016/j.crohns.2010.11.001. Epub 2010 Dec 7.

PMID:
21453886
5.
6.

Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.

af Björkesten CG, Nieminen U, Sipponen T, Turunen U, Arkkila P, Färkkilä M.

Scand J Gastroenterol. 2013 May;48(5):543-51. doi: 10.3109/00365521.2013.772230. Epub 2013 Mar 12.

PMID:
23477356
7.

Distinctive histopathologic phenotype in resection specimens from patients with Crohn's disease receiving anti-TNF-α therapy.

Schaeffer DF, Walsh JC, Kirsch R, Waterman M, Silverberg MS, Riddell RH.

Hum Pathol. 2014 Sep;45(9):1928-35. doi: 10.1016/j.humpath.2014.05.016. Epub 2014 Jun 12.

PMID:
25022570
8.

Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review.

Ochenrider MG, Patterson DJ, Aboulafia DM.

Clin Lymphoma Myeloma Leuk. 2010 Apr;10(2):144-8. doi: 10.3816/CLML.2010.n.021. Review.

PMID:
20371449
9.

Autoimmune hepatitis induced by infliximab in a patient with Crohn's disease with no relapse after switching to adalimumab.

Cravo M, Silva R, Serrano M.

BioDrugs. 2010 Dec 14;24 Suppl 1:25-7. doi: 10.2165/11586210-000000000-00000.

PMID:
21175232
10.

T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.

Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED.

Am J Gastroenterol. 2013 Jan;108(1):99-105. doi: 10.1038/ajg.2012.334. Epub 2012 Oct 2.

PMID:
23032984
11.

Patient outcomes after anti TNF-alpha drugs for Crohn's disease.

Assasi N, Blackhouse G, Xie F, Marshall JK, Irvine EJ, Gaebel K, Robertson D, Campbell K, Hopkins R, Goeree R.

Expert Rev Pharmacoecon Outcomes Res. 2010 Apr;10(2):163-75. doi: 10.1586/erp.10.13. Review.

PMID:
20384563
12.

Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data.

Rubin DT, Uluscu O, Sederman R.

Inflamm Bowel Dis. 2012 Dec;18(12):2225-31. doi: 10.1002/ibd.22925. Epub 2012 Feb 22.

PMID:
22359399
13.

Infliximab-induced acute hepatitis during Crohn's disease therapy: absence of cross-toxicity with adalimumab.

Haennig A, Bonnet D, Thebault S, Alric L.

Gastroenterol Clin Biol. 2010 Sep;34(8-9):e7-8. doi: 10.1016/j.gcb.2010.01.016. Epub 2010 Feb 26. No abstract available.

14.

Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.

Absah I, Faubion WA Jr.

Inflamm Bowel Dis. 2012 Aug;18(8):1488-92. doi: 10.1002/ibd.21885. Epub 2011 Aug 31.

PMID:
21882301
15.

Adalimumab for Crohn's disease after infliximab treatment failure: a systematic review.

Da W, Zhu J, Wang L, Lu Y.

Eur J Gastroenterol Hepatol. 2013 Aug;25(8):885-91. doi: 10.1097/MEG.0b013e32836220ab. Review.

PMID:
23817447
16.
17.

Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies.

Martín-de-Carpi J, Pociello N, Varea V.

J Crohns Colitis. 2010 Nov;4(5):594-8. doi: 10.1016/j.crohns.2010.04.002. Epub 2010 May 1.

PMID:
21122566
18.

First case report of adalimumab-induced psoriasis in Crohn's disease.

Harris MD, Richards R.

Am J Gastroenterol. 2009 Mar;104(3):792-3. doi: 10.1038/ajg.2008.101. Epub 2009 Feb 3. No abstract available.

PMID:
19262532
19.

Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease.

Riis A, Martinsen TC, Waldum HL, Fossmark R.

Scand J Gastroenterol. 2012 Jun;47(6):649-57. doi: 10.3109/00365521.2012.672591. Epub 2012 Apr 4.

PMID:
22472026
20.

Safety of adalimumab in Crohn's disease during pregnancy: case report and review of the literature.

Jürgens M, Brand S, Filik L, Hübener C, Hasbargen U, Beigel F, Tillack C, Göke B, Ochsenkühn T, Seiderer J.

Inflamm Bowel Dis. 2010 Oct;16(10):1634-6. doi: 10.1002/ibd.21198. No abstract available.

PMID:
20027647
Items per page

Supplemental Content

Write to the Help Desk